THANOCRINE Trademark

Trademark Overview


On Monday, December 14, 2020, a trademark application was filed for THANOCRINE with the United States Patent and Trademark Office. The USPTO has given the THANOCRINE trademark a serial number of 90379452. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 30, 2023. This trademark is owned by Inzen Therapeutics, Inc.. The THANOCRINE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical agents and products for cellular signal modulation for treating cancer, fibrotic diseases, immune and inflammatory diseases, neurological diseases, infectious disease, tissue degenerative diseases, regenerative medicine; therapeutic products for cellular signal modulation in the nature of chemical and biological small molecules; pharmaceutical compositions in the nature of chemical and biological small molecules for treatment of cancer, fibrotic diseases, immune and inflammatory diseases, neurological diseases, infectious disease, tissue degenerative diseases, regenerative medicine; pharmaceutical compositions in the nature of chemical and biological molecules for cellular signal modulation

Scientific research, pharmaceutical research, and medical research in the fields of pharmaceutical research and development and biotechnology for others; product development for others in the field of biotechnology; development of pharmaceuticals and therapeutic agents for others
thanocrine

General Information


Serial Number90379452
Word MarkTHANOCRINE
Filing DateMonday, December 14, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 30, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 2, 2021

Trademark Statements


Goods and ServicesPharmaceutical agents and products for cellular signal modulation for treating cancer, fibrotic diseases, immune and inflammatory diseases, neurological diseases, infectious disease, tissue degenerative diseases, regenerative medicine; therapeutic products for cellular signal modulation in the nature of chemical and biological small molecules; pharmaceutical compositions in the nature of chemical and biological small molecules for treatment of cancer, fibrotic diseases, immune and inflammatory diseases, neurological diseases, infectious disease, tissue degenerative diseases, regenerative medicine; pharmaceutical compositions in the nature of chemical and biological molecules for cellular signal modulation
Goods and ServicesScientific research, pharmaceutical research, and medical research in the fields of pharmaceutical research and development and biotechnology for others; product development for others in the field of biotechnology; development of pharmaceuticals and therapeutic agents for others

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, February 21, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, September 15, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSONATA THERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02142

Party NameInzen Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Party NameInzen Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Monday, January 30, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 30, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, January 4, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, June 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 22, 2022SOU EXTENSION 1 GRANTED
Wednesday, June 22, 2022SOU EXTENSION 1 FILED
Wednesday, June 22, 2022TEAS EXTENSION RECEIVED
Tuesday, December 28, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 2, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 2, 2021PUBLISHED FOR OPPOSITION
Wednesday, October 13, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 28, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 15, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 14, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 14, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 23, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 23, 2021NON-FINAL ACTION E-MAILED
Tuesday, March 23, 2021NON-FINAL ACTION WRITTEN
Monday, March 22, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 22, 2021NON-FINAL ACTION E-MAILED
Monday, March 22, 2021NON-FINAL ACTION WRITTEN
Wednesday, March 17, 2021ASSIGNED TO EXAMINER
Sunday, February 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED